GLP-1 medications drive shifts in diet and postpartum healthcare

Recent studies and surveys highlight the widespread impact of GLP-1 medications, such as Ozempic and Wegovy, on health and consumer behavior. In the United States, approximately 11% of adults now use these drugs for weight loss, a significant increase from 3% in 2024.

Research indicates shifting dietary patterns among users. A survey by Toast found that 51% of GLP-1 users eat restaurant meals less frequently, and 62% order less food when they do eat out. Common reductions include desserts, large entrées, and appetizers, while users report ordering more salads, lean proteins, and high-protein items.

Clinical findings have addressed safety and demographic trends. A large-scale study of over 2 million pregnancies led by City St George’s, University of London, found no clearly detectable increase in risks like miscarriage or congenital anomalies following inadvertent GLP-1 exposure around conception. However, other research involving patients in several countries noted that users may experience higher rates of hair loss and nail issues, such as discoloration or detachment.

In the U.S., there is a notable surge in postpartum prescriptions. Data from the USC Schaeffer Center shows that the share of new mothers starting GLP-1 treatments within six months of childbirth rose from 0.08% in 2018 to 1.9% in early 2025. This growth is most pronounced among women with type 2 diabetes and those with gestational diabetes.